Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Anticipation Of Acquisition, Resverlogix Spins Out Epigenetics Platform

This article was originally published in The Pink Sheet Daily

Executive Summary

The publicly listed Canadian biotech is prepping for a potential takeout after Phase IIb for its lead candidate by spinning out its preclinical epigenetics platform into a new private company. If Resverlogix is acquired, the newco could potentially gain a royalty from the acquirer in exchange for access to IP.

You may also be interested in...



Theravance To Split Into A Royalty Play and An R&D Company

With a pair of PDUFA dates this year, Theravance is thinking ahead how to pass potential royalties to investors while continuing to fund its pipeline. The biopharma said it would separate into two public companies: a royalty play to return cash to shareholders and an R&D pipeline story.

Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet

The biotech brings Roche on as its seventh biopharma partner, building on the more than $5 billion in potential partnership revenue the biotech had already amassed. If all goes as planned, Isis will add five marketed products within the next five years to the newly approved Kynamro. But Wall Street doesn’t expect Isis’ revenues to increase much anytime soon. Plus more notable deals this week…

Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel